Brief: Equillium Reports Q2 2021 Financial Results, Provides Clinical Development Update
Aug 10 (Reuters) - Equillium Inc EQ.O :
* EQUILLIUM REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS
AND
PROVIDES CLINICAL DEVELOPMENT UPDATE
* Q2 LOSS PER SHARE $0.31
* Q2 EARNINGS PER SHARE ESTIMATE $-0.31 -- REFINITIV IBES
DATA
* BELIEVES THAT ITS CASH AND INVESTMENTS WILL BE SUFFICIENT
TO
FUND ITS CURRENTLY PLANNED OPERATIONS INTO 2023
* CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED
$97.6
MILLION AS OF JUNE 30, 2021
Source text for Eikon: ID:nBw4ckmhwa
Further company coverage: EQ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations